Papers – Innovita Research

Papers

We have made a number of major publications on our technologies from 2012 to 2017:
  • Direct effects of interleukin-8 on growth and functional activity of T lymphocytes.
    Meniailo ME, Malashchenko VV., Shmarov VA, Gazatova ND, Melashchenko OB, Goncharov AG, Seledtsova G.V. Seledtsov VI. Int Immunopharmacol. 2017;
    In press.
  • A possible role for idiotype/anti-idiotype B-T cell interactions in maintaining immune memory.
    Seledtsov V.I., Seledtsova G.V. Front Immunol.. 2017; 8:409.
    https://www.ncbi.nlm.nih.gov/pubmed/28428787
  • Scaffold design for artificial tissue with bone marrow stem cells.
    Noreikaitė A, Antanavičiūtė I, Mikalayeva V, Darinskas A, Tamulevičius T, Adomavičiūtė E, Šimatonis L, Akramienė D, Stankevičius E. Medicina (Kaunas).. 2017;53(3):203-210. doi: 10.1016/j.medici.2017.07.001.
    https://www.ncbi.nlm.nih.gov/pubmed/28774494
  • Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study.
    Darinskas A, Paskevicius M, Apanavicius G, Vilkevicius G, Labanauskas L, Ichim TE, Rimdeika R. J Transl Med. 2017 Jun 19;15(1):143. doi: 10.1186/s12967-017-1243-3.
    https://www.ncbi.nlm.nih.gov/pubmed/28629476
  • Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.
    Kraśko JA, Žilionytė K, Darinskas A, Strioga M, Rjabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Lubitz W, Kudela P, Miseikyte-Kaubriene E, Karaman O, Didenko H, Potebnya H, Chekhun V, Pašukonienė V.Oncol Rep. 2017 Jan;37(1):171-178. doi: 10.3892/or.2016.5252. Epub 2016 Nov 16.
    https://www.ncbi.nlm.nih.gov/pubmed/27878261
  • Direct effects of interleukin-7 on the functionality of human T cells in vitro.
    Shmarov VA, Malashchenko VV, Meniailo ME, Gazatova ND, Todosenko NM, Melashchenko OB, Goncharov AG, Seledtsov VI. Eur Cytokine Netw. 2016; 27:102-7.
    https://www.ncbi.nlm.nih.gov/pubmed/28396296
  • Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosis.
    Seledtsova G.V., Ivanova I.P., Shishkov А.А., Seledtsov V.I. J Immunotox.. 2016; 13: 879–84.
    https://www.ncbi.nlm.nih.gov/pubmed/27602793
  • Xenonogeneic cell-based vaccine therapy for colorectal cancer: association of clinical effects with vaccine-induced immune responses.
    Seledtsova G.V., Shishkov A.A., Kaschenko E.A, Seledtsov V.I. Biomed Pharmacother.. 2016; 83: 1247-52.
    https://www.ncbi.nlm.nih.gov/pubmed/27565847
  • Xenonogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
    Seledtsova G.V., Shishkov A.A., Kaschenko E. A.,. Goncharov A. G., Gazatova N. D., Seledtsov V.I. Eur J Dermat.. 2016; 26: 138-43.
    https://www.ncbi.nlm.nih.gov/pubmed/27026566
  • Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes.
    Todosenko NM, Shmarov VA, Malashchenko VV, Meniailo ME, Melashchenko OB, Gazatova ND, Goncharov AG, Seledtsov VI. Int Immunopharmacol. 2016 ; 36: 277-81.
    https://www.ncbi.nlm.nih.gov/pubmed/27208431
  • A novel dual NO-donating oxime and c-Jun N-terminal kinase inhibitor protects against cerebral ischemia–reperfusion injury in mice.
    Atochin D.N., Schepetkin I.A., Khlebnikov A.I., Seledtsov V.I., Swanson H., Quinn M.T., Huang P.L. Neurosci Lett. 2016; 618:45-9.
    https://www.ncbi.nlm.nih.gov/pubmed/26923672
  • Multiple-purpose immunotherapy for cancer.
    Seledtsov V.I., Goncharov A.G., Seledtsova G.V. Biomedicine & Pharmacotherapy. 2015; 76: 24–9
    https://www.ncbi.nlm.nih.gov/pubmed/26653546
  • Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov V.I., Goncharov A.G., Seledtsova G.V. Human Vaccines & Immunotherapeutics.. 2015; 11(4):851-69.
    https://www.ncbi.nlm.nih.gov/pubmed/25933181
  • Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography.
    Mačiulaitis J, Deveikytė M, Rekštytė S, Bratchikov M, Darinskas A, Šimbelytė A, Daunoras G, Laurinavičienė A, Laurinavičius A, Gudas R, Malinauskas M, Mačiulaitis R. Biofabrication.. 2015 Mar 23;7(1):015015. doi: 10.1088/1758-5090/7/1/015015.
    https://www.ncbi.nlm.nih.gov/pubmed/25797444
  • Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis.
    Ivanova I.P, Seledtsova G.V., Mamaev S.V., Shishkov A.A., Seledtsov V.I. Human Vaccines & Immunotherapeutics.. 2014; 10: 1-7.
    https://www.ncbi.nlm.nih.gov/pubmed/24633313
  • Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V. Vaccine.2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/24837511
  • Investigations of cellular immunity in different stages of liver fibrosis.
    Seledtsov V.I., Seledtsova I.A., Gazatova N.D., Volchek E.I., Sidorova E.I. J. Hepatology. 2013; 58 (s1): 296.
  • A balance between tissue-destructive and tissue-protective immunities: a role of toll-like receptors in regulation of adaptive immunity.
    Seledtsov V.I., Seledtsova G.V. Immunobiology. 2012; 217: 430-5.
    https://www.ncbi.nlm.nih.gov/pubmed/22099351
  • Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells.
    Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Stem Cells Dev.. 2012 Sep 20;21(14):2724-52. doi: 10.1089/scd.2011.0722. Epub 2012 May 9. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/22468918
  • Xenovaccinotherapy for Cancer
    Seledtsov V.I. Shishkov A.A., Seledtsova G.V. In Current Cancer Treatment – Novel Beyond Conventional Approaches, Prof. Öner Özdemir (Ed.), ISBN: 978-953-307-397-2, InTech, 2011: 416-428. DOI: 10.5772/23671.
    Available from https://www.intechopen.com/articles/show/title/xenovaccinotherapy-for-cancer